



Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/540,494
				Filing Date	May 30, 2006
				First Named Inventor	Chieko Kitada
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	63628 (46342)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/CB/	BA	EPO 162 575	11-27-1985	The Salk Institute for Biological Studies		
	BB	JP9-169735	6-30-1997	Takeda Chemical Industries, Ltd.	WO 97/14682 enclosed	T
/CB/	BC	JP2003-026601	01-29-2003	Takeda Chemical Industries, Ltd.	See English Abstract	T
/CB/	BD	WO 97/40071	10-30-1997	Novo Nordisk A/S		
/CB/	BE	WO 2004/038021 A1	05-06-2004	Paradigm Therapeutics Limited		
/CB/	BF	WO 2004/063221 A1	07-29-2004	Takeda Chemical Industries, Ltd.	See U.S. 2006/0241051 A1 Enclosed	T
/CB/	BG	WO 2004/087622 A2	10-14-2004	Institut National De La Sante et De La Recherche Medicale, et al.		
/CB/	BH	WO 2004/096855 A2	11-11-2004	Wyeth		
/CB/	BI	WO-2004/101747 A2	11-25-2004	The General Hospital Corporation		
/CB/	BJ	WO 2004/106289 A1	12-09-2004	Combio A/S[DK/DK]		
/CB/	BK	WO 2005/095973 A2	10-13-2005	Bayer Healthcare AG		
/CB/	BL	WO 2006/001499 A2	01-05-2006	Takeda Pharmaceutical Company Limited		
/CB/	BM	WO 2007/072997 A1	06-28-2007	Takeda Pharmaceutical Company Limited		
/CB/	BN	WO 2007/084211 A2	07-26-2007	General Hospital Corporation, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Christina Bradley/ (07/23/2008)	Date Considered	
-----------------------	----------------------------------	--------------------	--

no copy

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/540,494
				Filing Date	May 30, 2006
				First Named Inventor	Chieko Kitada
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	1	Attorney Docket Number	63628 (46342)

include name of the author and title of the article

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Journal of the Chemical Society, <i>Perkin Transactions 1</i> , No. 2, 379-388		
	CB	Nature, 411, 613-617 (2001)		
	CC	The Journal of Clinical Endocrinology & Metabolism, 88, 914-919 (2003)		
	CD	Biochemical and Biophysical Research Communications 315, Toshihiko Masui, et al., 85-92 (2004)		
	CE	Biochemical and Biophysical Acta, 1678, Yasuko Terao, et al., 102-110 (2004)		
	CF	Endocrinology 145, 4073; M.L. Gattisch, et al., 4073-4077		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Attorney Docket No.: 63628 (46342)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM 053205010 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on

2/14/2008

Date _____

Tamara Rappoport
Signature

Signature _____

Louise Rappaport

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 239-0100

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS) (2 pages)
IDS (Citation) by Applicant (2 pages)
22 References
Return stamped postcard